Results 131 to 140 of about 26,261 (211)

Beyond glycemic control: Sex differences shaping glucagon-like peptide-1 receptor agonist utilization in the United States. [PDF]

J Manag Care Spec Pharm
Ofili SC, Chen H.
europepmc   +1 more source

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

Diabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo, Bianca Aparecida Siqueira, Luiz Felipe Azevedo Marques, Lucas Silva Mello, Fernando Augusto Lima Marson   +4 more
wiley   +1 more source

Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis. [PDF]

Cancers (Basel)
Ailawadi S, Murphy JE, Storandt MH, Mahipal A.   +3 more
europepmc   +1 more source

Perioperative glycaemic profiles in Aboriginal and Torres Strait Islander people with diabetes mellitus

Diabetic Medicine, EarlyView.
This large multicentre retrospective cohort study in Australia revealed that despite being younger and having greater preoperative comorbidity and higher HbA1c levels, Aboriginal and Torres Strait Islander adults with diabetes mellitus demonstrate higher rates of perioperative hypoglycaemia, but otherwise comparable markers of glycaemic variability and
Katerina Flabouris, Odette R. Pearson, Kim Morey, Suzanne M. Edwards, David R. Jesudason, Chinmay S. Marathe   +5 more
wiley   +1 more source

Preoperative Glucagon-Like Peptide-1 Receptor Agonist Treatment to Allow Safe Laparoscopic Left Pancreatectomy in Extreme Obesity: The First Report. [PDF]

Case Rep Surg
Canali G, Herfeld G, Averous G, Baltzinger P, Addeo P.   +4 more
europepmc   +1 more source

It's a game changer in terms of diabetic management’: A qualitative study of adolescents' and parents' experiences of a 6‐month trial of continuous glucose monitoring in type 2 diabetes

Diabetic Medicine, EarlyView.
Abstract Aim To qualitatively explore adolescents with type 2 diabetes (T2D) using any treatment regimen and parents of such adolescents' experiences of a 6‐month trial of continuous glucose monitoring (CGM) and its perceived barriers and facilitators.
Maheesha Fernando, Alexia S. Peña, Ashlee King, Melissa Oxlad   +3 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonist and respiratory complications after endoscopy: A Japanese nationwide cohort study. [PDF]

Diabetes Obes Metab
Hisada H, Ikeuchi K, Tsuji Y, Yamamichi N, Kakushima N, Okushin K, Yakabi S, Takeuchi C, Ohki D, Mizutani H, Miura Y, Kubota D, Tsutsumi T, Fujishiro M.   +13 more
europepmc   +1 more source

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This post hoc analysis of COMBINE 1–3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once‐weekly combination therapy of basal insulin icodec and semaglutide [a glucagon‐like peptide‐1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.
Linong Ji, Jonas Dahl Andersen, Malik Benamar, Paola Ponzani, A. G. Unnikrishnan, Siri Vinther, Rosangela Rea   +6 more
wiley   +1 more source

Perioperative Glucagon-Like Peptide-1 Receptor Agonist Therapy and Postoperative Outcomes in Adult Foot and Ankle Surgery: A Scoping Review. [PDF]

Cureus
Zahed M, Alesawy AF, Elkohail A, Ghazi A, Fell A, Hashem M.   +5 more
europepmc   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris, Djordje S. Popovic, Alexandros L. Liarakos, Alexandros Briasoulis, Nikolaos Papanas, Theocharis Koufakis   +5 more
wiley   +1 more source